Company Profile
Merck Stock Price, News & Analysis
- Ticker:
- MRK
- Exchange:
- NYSE
- Sector:
- Oncology, Immunotherapy, Vaccines
- Location:
- United States
Stock performance
128.37 USD (+0.03%)
Close
Last updated: August 6, 2026
286B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, MRK was little changed and closed at $128.37. No new same-company headline was identified in the current news window.
Company overview
Business overview
Merck is a diversified pharmaceutical company with major exposure to oncology, vaccines, infectious disease, and animal health. The company’s market story still revolves around Keytruda, pipeline replacement, and the durability of its broader portfolio.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NYSE, Merck has a global pharmaceutical footprint with strong international reach. It sits in large-cap biopharma and not in a narrow biotech niche.
Business Model Characteristics
Merck generates revenue from a mix of blockbuster products, vaccines, and pipeline assets. Investors watch oncology growth, patent lifecycle pressure, vaccine demand, and whether the next wave of products can offset concentration risk.
Position Within the Biotechnology Landscape
Merck is a mature large-cap pharma name with meaningful biotech-like catalyst sensitivity around oncology and vaccine updates. It is less volatile than clinical-stage companies, but major pipeline or label events can still move sentiment.
Future catalysts
Merck’s next three months are likely to focus on Winrevair uptake, oncology execution, and any pipeline readout that helps replace the market’s dependence on Keytruda. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Merck (MRK)?
Merck (MRK) most recently closed at 128.37 USD, a +0.03% move versus the previous session.
What is the market cap of Merck (MRK)?
Merck currently has a market capitalization of 286B USD on BioPharmSignal.
What does Merck do?
Merck is a diversified pharmaceutical company with major exposure to oncology, vaccines, infectious disease, and animal health. The company’s market story still revolves around Keytruda, pipeline replacement, and the durability of its broader portfolio.
On which exchange is MRK stock listed?
Merck (MRK) is associated with NYSE, United States, Oncology, Immunotherapy, Vaccines.
What is Merck?
Merck’s next three months are likely to focus on Winrevair uptake, oncology execution, and any pipeline readout that helps replace the market’s dependence on Keytruda.
Which conditions is Merck targeting with Merck?
Merck is associated with oncology based on its company overview and current catalyst commentary.
How does Merck describe recent progress with Merck?
Merck’s next three months are likely to focus on Winrevair uptake, oncology execution, and any pipeline readout that helps replace the market’s dependence on Keytruda.
What is Keytruda?
The company’s market story still revolves around Keytruda, pipeline replacement, and the durability of its broader portfolio.